Prognostic factors in early-stage triple-negative breast cancer: Lessons and limits from clinical practice

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2737-2742

  Pistelli, Mirco ^a   Pagliacci, Alessandra ^a   Battelli, Nicola ^a   Santinelli, Alfredo ^b   Biscotti, Tommasina ^b   Ballatore, Zelmira ^a   Berardi, Rossana ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Breast; Cancer; Lymphovascular; Size; Triple negative; Tumour

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; NAVELBINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT CHEMOTHERAPY; BREAST; BREAST TUMOR; LYMPH NODE METASTASIS; LYMPH VESSEL; MIDDLE AGED; MORTALITY; NEOPLASM; PATHOLOGY; PROGNOSIS; SIZE; TREATMENT OUTCOME; TRIPLE-NEGATIVE; TUMOR INVASION; VERY ELDERLY;

BREAST; CANCER; LYMPHOVASCULAR; SIZE; TRIPLE-NEGATIVE; TUMOUR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84881336064     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS and Millikan RC: Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 295(21): 2492-2502, 2006.
2. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER-2 negative invasive breast cancer, the so-called triple negative phenotype: A population-based study from the California Cancer Registry. Cancer 109(9): 1721-1728, 2007.
3. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K and Mitchell EP: Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A singleinstitution compilation compared with the National Cancer Institute's Surveillance, Epidemiology and End Results database. Cancer 110(4): 876-884, 2007.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triplenegative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
5. Perou CM: Molecular Stratification of Triple-Negative Breast Cancers. Oncologist 16(suppl 1): 61-70, 2011.
6. Prat A and Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 5: 5-23, 2011.
7. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: 5652-5657, 2006.
8. Anders CK and Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9(Suppl 2): S73-81, 2009.
9. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol 28: 3271-3277, 2010.
10. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A and du Bois A: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45(16): 2792-8, 2009.
11. Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: Therapeutic options. Lancet Oncol 8: 235-44, 2007.
12. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN and Gonzalez-Angulo AM: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24: 1037-44, 2006.
13. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN and Pusztai L: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-81, 2008.
14. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM and Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype. Clin Cancer Res 14: 1368-76, 2008.
15. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32, 2007.
16. Tang D, Xu S, Zhang Q and Zhao W: The expression and clinical significance of the androgen receptor and E-cadherin in triple negative breast cancer. Med Oncol 29(2): 526-33, 2012.
17. Loibl S, Muller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K and Denkert C: Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 130: 477-487, 2011.
18. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO and Foulkes WD: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7: 134, 2007.
19. Lai HW, Kuo SJ, Chen LS, Chi CW, Chen ST, Chang TW and Chen DR: Prognostic significance of triple negative breast cancer at tumour size 1 cm and smaller. Eur J Surg Oncol 37: 18-24, 2011.
20. Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R; Austrian Breastand Colorectal Cancer Study Group: Prognostic value of lymphangiogenesis and limphovascular invasion in invasive breast cancer. Ann Surg 240: 306-312, 2004.
21. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtio J and Lewensohn R: Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20: 1639-1646, 2009.
22. Mohammed RA, Ellis IO, Mahmmod AM, Hawkes EC, Green AR, Rakha EA and Martin SG: Lymphatic and blood vessels in basal and triple negative breast cancers: Characteristics and prognostic significance. Mod Pathol 24: 774-785, 2011.
23. Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Ikeda K, Ogawa Y, Ishikawa T and Hirakawa K: Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at stage II: Usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res 13(6): R122, 2011.
24. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M,Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-Analysis Study Group: HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: A meta-Analysis of individual patient data. Lancet Oncol 12(12): 1134-1142, 2011.
25. Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ,Bernard PS, Perou CM and Nielsen TO: Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.Clin Cancer Res 18(8): 2402-2412, 2012.
26. Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, Coates AS and Gusterson BA: Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy for nodenegative breast cancer. J Clin Oncol 28: 2966-2973, 2010.